Annual Revenue Comparison: BeiGene, Ltd. vs Sarepta Therapeutics, Inc.

Biotech Giants' Revenue Surge: BeiGene vs. Sarepta

__timestamp	BeiGene, Ltd.	Sarepta Therapeutics, Inc.
Wednesday, January 1, 2014	13035000	9757000
Thursday, January 1, 2015	8816000	1253000
Friday, January 1, 2016	1070000	5421000
Sunday, January 1, 2017	238387000	154584000
Monday, January 1, 2018	198220000	301034000
Tuesday, January 1, 2019	428212000	380833000
Wednesday, January 1, 2020	308874000	540099000
Friday, January 1, 2021	1176283000	701887000
Saturday, January 1, 2022	1415921000	933013000
Sunday, January 1, 2023	2458779000	1243336000

In pursuit of knowledge

A Tale of Two Biotechs: BeiGene vs. Sarepta

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success. Over the past decade, BeiGene, Ltd. and Sarepta Therapeutics, Inc. have been at the forefront of innovation, each carving out a unique path. From 2014 to 2023, BeiGene's revenue skyrocketed by an astounding 18,800%, reaching approximately $2.46 billion. In contrast, Sarepta's revenue grew by a remarkable 12,600%, culminating in around $1.24 billion. This growth reflects the companies' strategic advancements in oncology and genetic medicine, respectively. Notably, 2021 marked a pivotal year, with BeiGene surpassing the billion-dollar mark, while Sarepta continued its steady climb. As these biotech giants continue to innovate, their financial trajectories offer a fascinating glimpse into the future of healthcare.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025